Get the Stockscreener App
1.55
28.10%
0.34
After Hours:
1.55
In 8 Bio Inc stock is traded at $1.55, with a volume of 743.06K.
It is up +28.10% in the last 24 hours and down -8.82% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$1.21
Open:
$1.21
24h Volume:
743.06K
Relative Volume:
3.09
Market Cap:
$7.18M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-2.0667
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
-3.13%
1M Performance:
-8.82%
6M Performance:
-28.90%
1Y Performance:
-79.23%
1-Day Range:
$1.20
$1.58
1-Week Range:
$1.17
$1.58
52-Week Range:
$1.17
$12.53
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.55 | 5.61M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 115.75B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.36 | 80.71B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.73 | 52.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
852.04 | 52.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.76 | 37.29B | 447.02M | -1.18B | -906.14M | -6.1812 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
What technical signals suggest for GRI Bio Inc. stockEarnings Growth Report & Safe Entry Point Identification - Улправда
Why Cabaletta Bio Inc. stock remains on watchlistsJuly 2025 Institutional & Weekly High Conviction Trade Ideas - ulpravda.ru
INmune Bio Signs Sales Agreement With A.G.P./Alliance Global Partners - TradingView — Track All Markets
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook - BioMarin Pharmaceutical
Why GRI Bio Inc. stock remains on buy listsShare Buyback & Stepwise Trade Signal Implementation - Улправда
Korro Bio (KRRO) boosts Jeffrey Cerio salary, severance and RSU grant - Stock Titan
Can Third Harmonic Bio Inc. stock withstand economic slowdownTrade Risk Assessment & Reliable Entry Point Alerts - ulpravda.ru
Pre Market Movers: ALGS, PDSB, PCSA Swing Big - RTTNews
Kala Bio (NASDAQ: KALA) details dismissal of Deloitte as auditor - Stock Titan
KALA BIO (Nasdaq: KALA) details Lazar financing shift and 2026 meeting - Stock Titan
Owner RA Capital Management LP Buys 314,561 ($754.7K) Of Climb Bio Inc [CLYM] - TradingView — Track All Markets
[8-K] ImmunityBio, Inc. Reports Material Event | IBRX SEC FilingForm 8-K - Stock Titan
GRI Bio (Nasdaq: GRI) details closing of offering, equity over $2.5M post-transaction - Stock Titan
GRI Bio Announces Closing of $8.0 Million Public Offering - GlobeNewswire
GRI Bio (NASDAQ: GRI) details $6.7M equity deal and runway into Q4 2026 - Stock Titan
GRI Bio (NASDAQ: GRI) prices $8,000,000 offering of 10,666,667 shares at $0.75 - Stock Titan
Inmune Bio Ends Sales Agreement with RBC and BTIG - TipRanks
GRI Bio, Inc. Announces Positive Phase 2a Trial Results for GRI-0621 - TradingView
GRI Bio (NASDAQ: GRI) unveils Phase 2a IPF results showing favorable safety and collagen biomarker shifts - Stock Titan
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
GRI Bio (NASDAQ: GRI) updates Form S-1 with extensive warrant and contract exhibits - Stock Titan
Chmn Hoffman Buys 45,000 ($193.8K) Of Annovis Bio Inc [ANVS] - TradingView — Track All Markets
GRI Bio Reports Positive Phase 2a Trial Results for IPF Treatment - TradingView
GRI Bio (NASDAQ: GRI) reports Phase 2a IPF topline results for GRI-0621 - Stock Titan
GRI Bio (Nasdaq: GRI) reports positive IPF Phase 2a results and warrant offering - Stock Titan
The 4 billion won investment quietly implemented by Yuhan four years ago returned to a "large jackpo.. - 매일경제
Pres Kalowski Sells 9,072 ($31.4K) Of Q32 Bio Inc [QTTB] - TradingView
CEO Morrison Sells 22,506 ($77.9K) Of Q32 Bio Inc [QTTB] - TradingView
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Nuvation Bio (NUVB) Chief Medical Officer reports 150K share sale and option exercise - Stock Titan
Upstream Bio (NASDAQ:UPB) Shares Down 8%Here's What Happened - MarketBeat
INMB SEC FilingsInmune Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Palisade Bio (Nasdaq: PALI) appoints GI trials expert Izanec VP, Clinical Development - Stock Titan
Climb Bio, Inc. (CLYM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Risk Off: Will Passage Bio Inc. stock sustain high P E ratiosQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - moha.gov.vn
Officer Liu Files To Sell 10,000 Of Nuvation Bio Inc [NUVB] - TradingView
KALA BIO Form 3 shows CEO and director hold no KALA stock - Stock Titan
Can Korro Bio Inc. stock surprise with earnings upsideWeekly Profit Summary & Growth Focused Stock Pick Reports - BỘ NỘI VỤ
Nuvation Bio Inc Discontinues NUV-1511 Development - TradingView
Chmn Hoffman Buys 39,200 ($159.9K) Of Annovis Bio Inc [ANVS]-Amended - TradingView
KALA BIO, Inc. Announces Executive and Board Changes - TradingView
[8-K] KALA BIO, Inc. Reports Material Event | KALA SEC FilingForm 8-K - Stock Titan
Chmn Hoffman Buys 39,200 ($159.9K) Of Annovis Bio Inc [ANVS] - TradingView
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
ANVS insider Form 4 shows director buying Annovis Bio stock - Stock Titan
Officer Hattersley Sells 369,051 ($2.7M) Of Nuvation Bio Inc [NUVB] - TradingView
Chmn Hoffman Buys 20,000 ($69.9K) Of Annovis Bio Inc [ANVS] - TradingView
Officer Hanley Sells 200,000 ($1.4M) Of Nuvation Bio Inc [NUVB] - TradingView
Officer Hattersley Files To Sell 369,051 Of Nuvation Bio Inc [NUVB] - TradingView
Officer Liu Files To Sell 20,000 Of Nuvation Bio Inc [NUVB] - TradingView
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
1.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):